Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Update

Vincerx Pharma, Inc. (NASDAQ:VINC) saw a significant decrease in short interest in the month of February. As of February 15th, there was short interest totalling 108,500 shares, a decrease of 59.7% from the January 31st total of 269,200 shares. Approximately 5.7% of the company’s stock are sold short. Based on an average trading volume of 711,500 shares, the days-to-cover ratio is presently 0.2 days.

Vincerx Pharma Price Performance

Shares of Vincerx Pharma stock opened at $1.09 on Friday. The stock has a market cap of $2.44 million, a price-to-earnings ratio of -0.05 and a beta of 1.38. The firm’s 50-day moving average is $2.56 and its two-hundred day moving average is $7.16. Vincerx Pharma has a 1 year low of $1.05 and a 1 year high of $187.44.

About Vincerx Pharma

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.